China gives emergency approval for first specialised Covid treatment
BEIJING China's drug authority has granted emergency approval for the country's first specialised treatment against Covid-19, found in clinical trials to significantly reduce hospitalisations and deaths among high-risk patients.
The move comes as regulators around the world give the green light to treatments - particularly for high-risk groups - amid worries over the new Omicron variant.
China is also grappling with a growing number of studies that show its vaccines have lower efficacy rates than many of those made elsewhere.
In an official notice published on Wednesday, China's National Medical Products Administration said it has granted "emergency approval" for a monoclonal antibody treatment.
A monoclonal antibody is a type of protein that attaches to the spike protein of the coronavirus, reducing its ability to enter the body's cells.
The treatment involves a combination of two drugs, administered through injections, and can be used to treat certain cases that are at risk of progressing in severity, the drug authority said.
It was co-developed by Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences.
Trial data showed that the combination therapy could reduce the risk of hospitalisation and death in high-risk patients by around 80 per cent, Tsinghua University said in a statement. A state media report last month added that the treatment has also been used on patients infected in local flare-ups.
China is the latest to approve similar Covid-19 treatments, with British regulators last week also authorising an antibody treatment. EU health authorities have approved pills for emergency use too - involving antiviral medications that slow down illness by reducing the capacity of the virus to reproduce within the body.
While pills are easier to use, the most effective treatment for Covid-19 currently involves monoclonal antibodies, which are administered via a drip.
China has several conditionally approved vaccines as well, but their published efficacy rates lag behind those of rival jabs developed in other countries. - AFP